Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
← catalyst calendarSponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
336estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-02 | estimated | When the study began enrolling |
| Primary completion | 2025-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection
Interventions
- Biological: LR20062
- Biological: DTaP-HepB-IPV-Hib vaccine
Primary outcome
what the primary-completion date above is the date OFSeroprotection/vaccine-response rate
measured 1 month after the third dose primary series
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed